MX2021000089A - Derivados de fenil-n-quinolina para el tratamiento de una infeccion por virus de acido ribonucleico (arn). - Google Patents

Derivados de fenil-n-quinolina para el tratamiento de una infeccion por virus de acido ribonucleico (arn).

Info

Publication number
MX2021000089A
MX2021000089A MX2021000089A MX2021000089A MX2021000089A MX 2021000089 A MX2021000089 A MX 2021000089A MX 2021000089 A MX2021000089 A MX 2021000089A MX 2021000089 A MX2021000089 A MX 2021000089A MX 2021000089 A MX2021000089 A MX 2021000089A
Authority
MX
Mexico
Prior art keywords
sub
group
sup
virus infection
rna virus
Prior art date
Application number
MX2021000089A
Other languages
English (en)
Spanish (es)
Inventor
Romain Najman
Didier Scherrer
Florence Mahuteau-Betzer
Julien Santo
Jamal Tazi
Cécile Apolit
Original Assignee
Abivax
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abivax filed Critical Abivax
Publication of MX2021000089A publication Critical patent/MX2021000089A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
MX2021000089A 2018-07-09 2019-07-09 Derivados de fenil-n-quinolina para el tratamiento de una infeccion por virus de acido ribonucleico (arn). MX2021000089A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18305910.4A EP3594206A1 (en) 2018-07-09 2018-07-09 Phenyl-n-quinoline derivatives for treating a rna virus infection
PCT/EP2019/068459 WO2020011810A1 (en) 2018-07-09 2019-07-09 Phenyl-n-quinoline derivatives for treating a rna virus infection

Publications (1)

Publication Number Publication Date
MX2021000089A true MX2021000089A (es) 2021-03-25

Family

ID=63035966

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021000089A MX2021000089A (es) 2018-07-09 2019-07-09 Derivados de fenil-n-quinolina para el tratamiento de una infeccion por virus de acido ribonucleico (arn).

Country Status (10)

Country Link
US (3) US12084422B2 (enExample)
EP (2) EP3594206A1 (enExample)
JP (2) JP7504409B2 (enExample)
KR (1) KR102758510B1 (enExample)
CN (1) CN112566899B (enExample)
AU (1) AU2019300100B2 (enExample)
BR (1) BR112021000331A2 (enExample)
CU (1) CU24674B1 (enExample)
MX (1) MX2021000089A (enExample)
WO (1) WO2020011810A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3594206A1 (en) * 2018-07-09 2020-01-15 Abivax Phenyl-n-quinoline derivatives for treating a rna virus infection
EP3999493B1 (en) 2019-07-19 2023-12-20 Abivax Aryl-n-aryl derivatives for treating a rna virus infection
BR112022018793A2 (pt) 2020-03-20 2022-11-29 Abivax Uso de um composto de fórmula (i) ou (ii) para tratar ou previnir uma infecção por coronaviridae e condições relacionadas, composição farmacêutica e medicamento compreendendo os mesmos, uso de um mirna como um biomarcador de uma infecção por coronaviridae, e método para avaliar uma infecção por coronaviridae
EP3884946A1 (en) 2020-03-25 2021-09-29 Abivax Compounds for treating or preventing a coronaviridae infection & methods and uses for assessing the occurrence of a coronaviridae infection
EP3881844A1 (en) 2020-03-20 2021-09-22 Abivax Compounds for treating or preventing a coronaviridae infection & methods and uses for assessing the occurrence of a coronaviridae infection
IL326865A (en) * 2023-08-30 2026-04-01 Jiangsu Chia Tai Fenghai Pharmaceutical Co Ltd Compound for regulating activity of microrna-124
CN122514519A (zh) * 2024-01-11 2026-08-04 豪夫迈·罗氏有限公司 杂芳基苯基醚衍生物

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070244120A1 (en) 2000-08-18 2007-10-18 Jacques Dumas Inhibition of raf kinase using substituted heterocyclic ureas
US7429599B2 (en) 2000-12-06 2008-09-30 Signal Pharmaceuticals, Llc Methods for treating or preventing an inflammatory or metabolic condition or inhibiting JNK
FR2830862A1 (fr) 2001-10-16 2003-04-18 Lipha Derives nitroso de la diphenylamine a fonction ether ou thioether, compositions pharmaceutiques les contenant et leur utilisation pour la preparation de medicaments
FR2836917B1 (fr) 2002-03-11 2006-02-24 Lipha Derives nitroso de la diphenylamine, compositions pharmaceutiques les contenant en tant que medicaments utilisables dans le traitement des pathologies caracterisees par une situation de stress oxydatif
AP2006003552A0 (en) 2003-08-21 2006-04-30 Osi Pharm Inc N3 - substituted imidazopyridine C-kit inhibitors.
FR2859474B1 (fr) 2003-09-04 2006-01-13 Centre Nat Rech Scient Utilisation de composes derives d'indole pour la preparation d'un medicament utile pour le traitement de maladies genetiques resultant de l'alteration des processus d'epissage
ATE435222T1 (de) 2003-12-18 2009-07-15 Tibotec Pharm Ltd Aminobenzimidazole und benzimidazole als inhibitoren der replikation von respiratory syncytial virus
FR2866647B1 (fr) * 2004-02-20 2006-10-27 Servier Lab Nouveaux derives azabicycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US20060069110A1 (en) 2004-09-27 2006-03-30 Andersen Denise L Substituted heterocyclic compounds and methods of use
RU2410382C2 (ru) 2005-03-17 2011-01-27 Тиботек Фармасьютикалз Лтд 1, 3-дигидробензимидазол-2-илиденовые амины в качестве ингибиторов репликации респираторного синцитиального вируса
US9409856B2 (en) 2005-11-28 2016-08-09 Gtx, Inc. Estrogen receptor ligands and methods of use thereof
WO2007081517A2 (en) 2005-12-21 2007-07-19 Abbott Laboratories Anti-viral compounds
WO2007076035A2 (en) 2005-12-21 2007-07-05 Abbott Laboratories Anti-viral compounds
FR2901273B1 (fr) 2006-05-19 2010-12-24 Anaconda Pharma Inhibiteurs du virus du papillome humain et les compositions pharmaceutiques les contenant
FR2926297B1 (fr) 2008-01-10 2013-03-08 Centre Nat Rech Scient Molecules chimiques inhibitrices du mecanisme d'epissage pour traiter des maladies resultant d'anomalies d'epissage.
US20140187641A1 (en) 2012-08-23 2014-07-03 Gtx Estrogen receptor ligands and methods of use thereof
CN102625804B (zh) 2009-06-12 2015-04-08 Abivax公司 用于治疗aids的化合物
JP2011026251A (ja) 2009-07-27 2011-02-10 Kowa Co 2−アリールアミノキノリン化合物及びこれを有効成分として含有するエリスロポエチン産生促進剤
AU2011270994B2 (en) 2010-06-24 2015-12-10 Takeda Pharmaceutical Company Limited Fused heterocyclic compounds as phosphodiesterases (PDES) inhibitors
EP2465502A1 (en) * 2010-12-15 2012-06-20 Société Splicos Compounds useful for treating AIDS
EP2505198A1 (en) 2011-04-01 2012-10-03 Société Splicos Compounds for use as therapeutic agents affecting p53 expression and/or activity
WO2014164667A1 (en) 2013-03-11 2014-10-09 Georgetown University Dengue and west nile virus protease inhibitors
CA2916623C (en) * 2013-07-05 2021-09-14 Abivax Bicyclic compounds useful for treating diseases caused by retroviruses
RU2628800C2 (ru) 2014-03-12 2017-08-22 Общество С Ограниченной Ответственностью "Фарминтерпрайсез" Амидные соединения, способы получения, применение в качестве средств для лечения и профилактики заболеваний, вызываемых рнк-содержащими вирусами
WO2016086153A2 (en) 2014-11-26 2016-06-02 Esanex, Inc. Use of tetrahydro!ndazolylbeimzamide and tetrahydroindolylbenzamide derivatives for the treatment of human immunodeficiency virus (hiv) and acquired immune deficiency syndrome (aids)
EP3059591A1 (en) * 2015-02-23 2016-08-24 Abivax Methods for screening compounds for treating or preventing a viral infection or a virus-related condition
EP3058940A1 (en) * 2015-02-23 2016-08-24 Abivax Quinoline derivatives for use in the treatment or prevention of viral infection
WO2017158201A1 (en) 2016-03-18 2017-09-21 Ratiopharm Gmbh Process for preparing quinolin-2-yl-phenylamine derivatives and their salts
EP3594206A1 (en) * 2018-07-09 2020-01-15 Abivax Phenyl-n-quinoline derivatives for treating a rna virus infection

Also Published As

Publication number Publication date
CN112566899A (zh) 2021-03-26
EP3594206A1 (en) 2020-01-15
CA3103867A1 (en) 2020-01-16
KR102758510B1 (ko) 2025-01-22
JP2024053563A (ja) 2024-04-15
WO2020011810A1 (en) 2020-01-16
JP7504409B2 (ja) 2024-06-24
US12084422B2 (en) 2024-09-10
JP7673362B2 (ja) 2025-05-09
CU24674B1 (es) 2023-08-08
AU2019300100B2 (en) 2024-10-24
EP3820852A1 (en) 2021-05-19
US12479802B2 (en) 2025-11-25
US20210309611A1 (en) 2021-10-07
AU2019300100A1 (en) 2021-01-21
US20260035348A1 (en) 2026-02-05
CN112566899B (zh) 2024-01-30
JP2021524481A (ja) 2021-09-13
BR112021000331A2 (pt) 2021-04-06
CU20210006A7 (es) 2021-08-06
KR20210052432A (ko) 2021-05-10
US20240308964A1 (en) 2024-09-19

Similar Documents

Publication Publication Date Title
RU2500680C2 (ru) Новые замещенные пиридин-2-оны и пиридазин-3-оны
MX2017002241A (es) Compuestos de aminopirimidina como inhibidores de jak.
MX2020011294A (es) Derivados de 2-amino-piridina o 2-amino-pirimidina como inhibidores de cinasa dependientes de ciclina.
WO2003080580A3 (en) Quinoline derivatives and their use as 5-ht6 ligands
MX2021000095A (es) Derivados de aril-n-arilo para el tratamiento de una infeccion por virus de acido ribonucleico (arn).
WO2003024967A3 (en) Indolizines as kinase protein inhibitors
NO20073926L (no) Pyrazolforbindelser som modulerer aktivitet av CDK-, GSK- og aurorakinaser
TW200833675A (en) Nicotinamide derivatives
NO20081582L (no) Benzamidforbindelser anvendbare som histon-deacetylaseinhibitorer
MXPA05010712A (es) Derivados de quinolin-2-ona para el tratamiento de enfermedades de las vias respiratorias.
MX380516B (es) Procedimiento para la preparacion del acido 4-fenil-5-alcoxicarbonil-2-tiazol-2-il-1,4-dihidropirimidin-6-il-[metil]3-oxo-5,6,8,8a-tetrahidro-1h-imidazo[1,5a]pirazin-2-il-carboxilico
SE0104332D0 (sv) Therapeutic agents
HUP0103988A2 (en) New d3-dopamine receptor selective piperazine and piperidine compounds, process for their preparation, their and pharmaceutical compositions containing them
CY1111980T1 (el) Παραγωγα του αμιδιου τα οποια φερουν ενα υποκαταστατο του κυκλοπροπυλαμινοκαρβονυλιου και χρησιμευουν ως αναστολεις κυτταροκινης
JOP20190113A1 (ar) مثبطات بروتون تيروزين كيناز
MA40480B1 (fr) Procédé de cristallisation de dérivés d'aripiprazole dans des formulations à libération prolongée pour le traitement de la schizophrénie
IL183373A0 (en) 3-[2-(3-acylamino-2-oxo-2h-pyridin-1-yl)-acetylamino]-4-oxo-pentanoic acid derivatives, pharmaceutical compositions containing the same and methods for the preparation thereof
TW200745066A (en) Novel PTP1B inhibitors
EP4316504A3 (en) Compounds
ATE413876T1 (de) Indolamid-derivate, die glycogen phosphorylase inhibierende aktivität besitzen
ATE429429T1 (de) Pharmazeutisches verfahren und damit hergestellte verbindungen
EA014959B3 (ru) Ингибиторы глицинового переносчика-1
NO20065327L (no) Fremgangsmate for fremstilling av derivarer av 5-'4-(2-hydroksy-propyl)-3,5-dihydro-3H'1, 2,4(triazin-2-yl)-benzamid.
CL2025003716A1 (es) Forma sólida de un compuesto de carboxamida de quinolina.
MX2023008250A (es) Compuestos de derivados sustituidos en 4,6 de ip4.